methotrexate and tirzepatide autoimmune disease: what the research actually shows Retatrutide vs Tirzepatide (2026): Differences

The relationship between body weight and optimal dosing has not been established through controlled trials

Can rapid weight loss from injections cause musculoskeletal discomfort

Peripheral inflammatory markers in autism spectrum disorder and attention deficit/hyperactivity disorder at adolescent age

Iyanda A, Anetor J, Adeniyi F, et al

Absolute Contraindications Active malignancy Pregnancy and lactation Severe hypoglycemia disorders Known hypersensitivity to IGF-1 Active proliferative retinopathy Relative Contraindications Diabetes mellitus Renal impairment Cardiac impairment History of hyperplasia Family history of certain cancers Severe hepatic impairment Dosing & Administration Starting Dose 2050 mcg/day subcutaneously Begin at the lower end for sensitive patients Assess tolerance for 12 weeks before titration Therapeutic Range 50120 mcg/day for most indications Maximum dose: 200 mcg/day Individualize dosing based on response and tolerance Cycling Protocol 46 weeks on therapy 4 weeks off therapy Helps prevent receptor desensitization Supports long-term efficacy Administration Guidelines Hypoglycemia Prevention: Always administer IGF-1 LR3 with or shortly after carbohydrate-containing meals